Novo Nordisk partners with OpenAI to accelerate drug discovery
Novo Nordisk announced a collaboration with OpenAI to deploy artificial intelligence across drug discovery, manufacturing, and commercial operations. The Danish pharmaceutical company will use OpenAI's technology to analyze complex datasets and identify promising drug candidates, while also improving supply chain efficiency and procurement.
Novo Nordisk competes directly with Eli Lilly in the weight-loss drug market, where both companies produce competing medications. The partnership signals a strategic move to regain market share through AI-driven innovation.
The companies expect pilot programs to begin immediately, with full integration by the end of 2026. Financial terms remain undisclosed.
How AI will be deployed
OpenAI's tools will help Novo Nordisk's researchers assess large datasets to narrow down potential drug candidates. The technology can perform molecular design in hours rather than years, compressing what traditionally takes lengthy laboratory work.
Beyond discovery, the AI will streamline tedious aspects of drug development: identifying clinical trial participants, selecting research sites, and drafting regulatory filings.
OpenAI will also train Novo Nordisk's workforce in AI literacy and technical skills needed to use the tools effectively.
Will AI replace scientists?
Novo Nordisk CEO Mike Doustda said the goal is not replacement. "The aim here is not to replace our scientists. It's about supercharging them," he said.
OpenAI's leadership echoed this framing. "AI is reshaping industries and in life sciences, it can help people live better, longer lives," an OpenAI executive said. "This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care."
AI's track record in drug development
Researchers at MIT used generative AI to design novel antibiotics targeting two drug-resistant infections: gonorrhea and methicillin-resistant Staphylococcus aureus (MRSA). The AI identified molecular structures that laboratory testing confirmed were effective.
AI models can also repurpose existing drugs by mapping the world's 8,000 approved medications against 17,000 diseases, identifying potential new uses without starting from scratch.
Despite these successes, AI for science and research has not yet solved what researchers call the "holy grail" of drug development-though the field continues advancing rapidly.
The partnership reflects a broader trend: pharmaceutical companies increasingly rely on AI to handle routine tasks, freeing scientists to focus on higher-level analysis and decision-making.
Your membership also unlocks:
